Quantifying Absolute Neutralization Titers against SARS-CoV-2 by a Standardized Virus Neutralization Assay Allows for Cross-Cohort Comparisons of COVID-19 Sera
oleh: Kasopefoluwa Y. Oguntuyo, Christian S. Stevens, Chuan Tien Hung, Satoshi Ikegame, Joshua A. Acklin, Shreyas S. Kowdle, Jillian C. Carmichael, Hsin-Ping Chiu, Kristopher D. Azarm, Griffin D. Haas, Fatima Amanat, Jéromine Klingler, Ian Baine, Suzanne Arinsburg, Juan C. Bandres, Mohammed N. A. Siddiquey, Robert M. Schilke, Matthew D. Woolard, Hongbo Zhang, Andrew J. Duty, Thomas A. Kraus, Thomas M. Moran, Domenico Tortorella, Jean K. Lim, Andrea V. Gamarnik, Catarina E. Hioe, Susan Zolla-Pazner, Stanimir S. Ivanov, Jeremy P. Kamil, Florian Krammer, Benhur Lee
| Format: | Article |
|---|---|
| Diterbitkan: | American Society for Microbiology 2021-02-01 |
Deskripsi
Vaccines and antibody-based therapeutics like convalescent-phase plasma therapy are premised upon inducing or transferring neutralizing antibodies that inhibit SARS-CoV-2 entry into cells. Virus neutralization assays (VNAs) for measuring neutralizing antibody titers (NATs) are an essential part of determining vaccine or therapeutic efficacy.